Oncology
Conference Coverage
What is the optimal duration of maintenance in myeloma?
SAN FRANCISCO – Dr. Yvonne A. Efebera and Dr. Nina Shah debate whether patients with multiple myeloma should receive maintenance until progression...
Outcomes Research in Review
AUGMENT: Lenalidomide/Rituximab vs Placebo/Rituximab in Relapsed or Refractory Indolent Lymphoma
Clinical Review
Role of Yoga Across the Cancer Care Continuum: From Diagnosis Through Survivorship
News
Q&A: Drug costs and value in cancer
Dr. Richard L. Schilsky, chief medical officer at ASCO, tackles the issue of how to determine the value of cancer drugs.
Conference Coverage
PACIFIC: Patterns of lung cancer progression suggest role for local ablative therapy
Approximately two-thirds of patients with distant progression had one or two new lesions.
News
Many institutions exceed recommended radiation doses during lung cancer screening
Allowing any radiologist, rather than a lead radiologist, to establish CT protocols is associated with high likelihood of exceeding ACR dose...
News
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
FDA/CDC
FDA issues warning for CDK 4/6 inhibitors
In a review of trials and postmarket safety databases, the FDA found there were reports of serious cases of pneumonitis, including fatalities,...
Article
Medical Cannabis: A guide to the clinical and legal landscapes
If your patient expresses interest in medical marijuana, you’ll find evidence on maximizing benefit while minimizing risk. But be cautious: Data...
News
USPSTF recommends preventive breast cancer medications only for women at risk
The USPSTF finds minimal value in medications to help prevent breast cancer for women not at increased risk